Results 201 to 210 of about 100,944 (279)

Prognostic Factors and Clinical Prediction Score for Progressive Respiratory Failure in Severe COVID-19 Pneumonia Patients Treated with Tocilizumab: A Multicenter Study. [PDF]

Ther Clin Risk Manag
Pongtarakulpanit N, Jayanama K, Phinyo P, Naothavorn W, Nuprom S, Pitidhammabhorn D, Ngammisri P, Ngamjanyaporn P, Suthichatchawan V, Wicharit L, Thammavaranucupt K.   +10 more
europepmc   +1 more source

Randomized Phase 1 Studies Evaluating the Safety, Tolerability, Pharmacokinetics, and Target Occupancy of Zampilimab in Healthy Participants

Clinical Pharmacology in Drug Development, Volume 15, Issue 5, May 2026.
Abstract Zampilimab (UCB7858) is a humanized monoclonal immunoglobulin G4P, transglutaminase 2 (TG2) inhibiting antibody. We investigated safety, tolerability, pharmacokinetics, and target occupancy of zampilimab (intravenous ≤2000 mg; subcutaneous ≤1000 mg) in healthy participants in a randomized, placebo‑controlled, single‐ascending‐dose Phase 1 ...
Jo Collier, Rowann Bowcutt, Geoffrey I. Johnston, Jane Y. C. Chan, Anastasiia Raievska, Alison Bigley, Richard Nicholl, Tim S. Schmidt, Maria Sarno, Zahid Ali, Elizabeth Thomson   +10 more
wiley   +1 more source

Exploring pathways leading to drug‐resistant epilepsy for patients with cryptogenic new onset refractory status epilepticus

Epilepsia, Volume 67, Issue 5, Page 2326-2346, May 2026.
Abstract Objective Cryptogenic new onset refractory status epilepticus (cNORSE) carries high risks of long‐term disability and post‐NORSE epilepsy, but mechanisms remain unclear. We aimed to assess the predictive value of inflammatory and brain injury biomarkers and determine whether immune disturbances persist in the chronic phase. Methods We enrolled
Aurélie Hanin, Clémence Marois, Martin Guillemaud, Mario Chavez, Léa Cosme, Zineb Hayatou, Aurore Besnard, Gwen Goudard, Véronique Masson, Louis Cousyn, Margaux Cheval, Jérôme A. Denis, Rana Alkouri, Foudil Lamari, Francesca Bisulli, Krista Eschbach, Raquel Farias‐Moeller, Nicolas Gaspard, Elizabeth E. Gerard, Giada Giovannini, Teneille Gofton, Margaret T. Gopaul, Marissa Kellogg, Stefano Meletti, Lorenzo Muccioli, Elena Pasini, Olga Taraschenko, Nathan Torcida, Mark S. Wainwright, Ji Yeoun Yoo, Nora Wong, Dominique Bonnefont‐Rousselot, Sophie Demeret, Lawrence J. Hirsch, Vincent Navarro   +34 more
wiley   +1 more source

Ready or not, here they come: a practical guide to adoptive T-cell therapies for solid tumors for medical oncologists. [PDF]

Oncologist
Hoang T, Khan S, Sacher A.
europepmc   +1 more source

Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Varnimcabtagene autoleucel (var‐cel) is an autologous CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy administered using an adaptive, fractionated dosing strategy. We conducted a multicenter retrospective study to evaluate the safety and efficacy of var‐cel in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL ...
Nil Albiol, Nuria Martínez‐Cibrián, Amanda Isabel Pérez, Sergio Navarro‐Velázquez, Guilherme Muzzi, Aina Oliver‐Caldes, Marta Español‐Rego, Leticia Alserawan, Mercedes Montoro‐Lorite, Carla Ramos, Pilar Ayora, Ana África Martin‐López, Almudena Cabero, Estefanía Pérez‐López, Alejandro Martín García‐Sancho, Tycho Baumann, José María Sánchez‐Pina, Anabelle Chinea, Paula Fernández‐Caldas, Mariana Bastos‐Oreiro, Mi Kwon, Luis Gerardo Rodríguez‐Lobato, Laura Magnano, Andrea Rivero, Juan G. Correa, Pablo Mozas, María Sánchez‐Castañón, Juan J. Mata‐Molanes, Paola Charry, Jose R. Álamo, Xavier Setoaín, Sonia Rodríguez, Eulalia Olesti, Joaquín Sáez‐Peñataro, Carlos Fernández de Larrea, Álvaro Urbano‐Ispizua, Armando López‐Guillermo, Julio Delgado, E. Azucena González‐Navarro, Manel Juan, Eva Giné, Valentín Ortiz‐Maldonado   +41 more
wiley   +1 more source

Successful use of Remcyte®-based continuous hemodiafiltration in a case of refractory CRS and ICANS complicated by tumor lysis syndrome-associated AKI. [PDF]

CEN Case Rep
Yomogida D, Hasegawa S, Mizuta S, Horikawa S, Koshida Y.   +4 more
europepmc   +1 more source

The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost‐effectiveness. Biosimilars—biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including ...
Zubaier Ahmed, Tasfiah Tasnim Maha, Sanjana Nowsher, Wasima Taslim, Fatema‐Tuz‐Zohora, Sabrina Sharmin, Hasina Yasmin   +6 more
wiley   +1 more source

Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis. [PDF]

Rheumatology (Oxford)
Goldman NR, Nihtyanova SI, Beesley CF, Wells AU, Denton CP, Renzoni EA, Mageed R, Ong VH.   +7 more
europepmc   +1 more source

Viral Mechanisms and Drug Influences on Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) Pathway in Human Coronaviruses Infection: A Systematic Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aim Janus kinases/signal transducers and activators of transcription (JAK/STAT) pathway is crucial for various stages of immunity, from innate to adaptive responses. Type 1 IFNs activate JAK/STAT pathway by binding to receptors on JAK, phosphorylating STAT and upregulating interferon‐stimulated genes (ISGs) leading to cytokines ...
Esimebia Adjovi Amegashie, Ruth Oyawole Sikeola, Caleb Koranteng Kwayisi‐Darkwah, Gabriel Atampugbire, Emmanuel Ayitey Tagoe, Elijah Paintsil, Kwasi Torpey, Osbourne Quaye   +7 more
wiley   +1 more source

Emapalumab in pediatric patients with high-grade cytokine release syndrome associated with CAR T-cell therapy. [PDF]

Front Immunol
Zhang J, Shi W, Yang J, Qian J, Su M, An K, Wang T, Jia R, Fei C, Tang Y, Li B.   +10 more
europepmc   +1 more source